A short, 9-month regimen of normal-dose moxifloxacin maintained good effectiveness up to 24 months after the cessation of therapy in patients with rifampicin-resistant tuberculosis (RR-TB), according to the results of an observational cohort study published in EClinicalMedicine.

New articles highlight emergence of resistance to bedaquiline and underline the need for improved susceptibility testing.

The Stop TB Partnership released the first edition of its quarterly newsletter for 2020 detailing the progress and results achieved in the priority countries of the Global Fund’s Strategic Initiative to Find the Missing People with TB.

02 March 2020, Geneva, Switzerland - Stop TB Partnership’s Global Drug Facility (GDF), Eiken Chemical Co., Ltd (Eiken) and Human Gesellschaft für Biochemica und Diagnostica mbH (HUMAN) announced today an agreement to reduce the price of the TB-LAMP test by over 30%.

The CDC and National Tuberculosis Controllers Association, or NTCA, has published updated recommendations for latent tuberculosis, or LTBI, in the MMWR for the first time since 2000.

A clinical review, published in The BMJ, summarized the current state of TB treatment with an emphasis on the ongoing clinical trials to anticipate how guidelines may change in the coming years.

Indian Government is now looking to buy delamanid for the first time from Otsuka.

The European Centre for Disease Prevention and Control (ECDC) and the World Health Organization (WHO) released a joint report reviewing the TB prevention and care system in the Netherlands.

-- A new global collaboration of philanthropic, non-profit and private sector organizations will work together to accelerate the development of novel TB treatment regimens for all TB patients.
-- The global collaboration aims to create treatment regimens comprised of medicines to which there is limited or no drug resistance and that are ready for phase 3 development.
-- The regimens could be an important step toward addressing the current global challenges around TB treatment complexity, and the diagnosis and treatment of drug-resistant TB.